+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients



Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients



Journal of Acquired Immune Deficiency Syndromes 38(5): 627-628




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048920775

Download citation: RISBibTeXText

PMID: 15793377

DOI: 10.1097/01.qai.0000159322.21133.74


Related references

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis. Colombia Medica 48(2): 70-81, 2017

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. Journal of Antimicrobial ChemoTherapy 64(6): 1260-1264, 2009

Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. Aids Research and Human Retroviruses 25(12): 1277-1285, 2009

Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). Journal of Acquired Immune Deficiency Syndromes 41(5): 598-606, 2006

Fixed-dose combination of abacavir, lamivudine and zidovudine for HIV therapy. Future Virology 2(1): 23-30, 2007

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. Aids 12(16): F197-F202, 1998

Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. Expert Opinion on PharmacoTherapy 8(4): 477-483, 2007

Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). Journal of Acquired Immune Deficiency Syndromes 40(4): 422-427, 2005

Abacavir/lamivudine fixed dose combination in the treatment of patients with HIV infection. HIV Therapy 3(1): 19-29, 2009

A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. PharmacoTherapy 21(4): 424-430, 2001

Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. HIV Clinical Trials 4(4): 231-243, 2003

Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada). Journal of Antimicrobial ChemoTherapy 61(2): 462-463, 2008

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data. Open Aids Journal 4: 167-170, 2010

Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clinical Trials 9(2): 103-114, 2008

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection. Terapevticheskii Arkhiv 86(11): 34-41, 2014